20 results on '"Prockop S"'
Search Results
2. Hematopoietic Stem/Progenitor Cells and Engineering: REAL WORLD USE OF THE PEDIATRIC DISEASE RISK INDEX FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER STUDY
3. Hematopoietic Stem/Progenitor Cells and Engineering: EARLY CD4 T CELL IMMUNE RECONSTITUTION AFTER HCT IS ASSOCIATED WITH REDUCED NON- RELAPSE RELATED MORTALITY BUT NOT WITH DECREASED RELAPSE RISK
4. 1051P Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease
5. Treatment with Banked 3rd Party Donor Derived Virus Specific T Cells: The Advantages of Pre-Defined HLA restriction and Epitope Specificity
6. Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel correlates with response & survival in rituximab relapsing or refractory EBV posttransplant lymphoproliferative disease (PTLD)
7. Durable responses to 3rd party viral specific T cells mediated by different patterns of engraftment
8. Comparison of two T-cell depletion methods of grafts from alternative donors for allogeneic hematopoietic cell transplantation of patients with fanconi anemia.
9. In T-cell lines dually sensitized with antigens from EBV and CMV or from EBV and WT1 the T-cells specific for CMV or WT1 are often restricted by hla alleles that differ from those restricting T-cells specific for EBV
10. Efficacy and safety of tabelecleucel in patients with EpsteinBarr Virus-associated leiomyosarcomas (EBV+ LMS)
11. Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match
12. Factors Contributing to Viral Infections and the Limited Efficacy of Adoptively Transferred Donor Derived Immunodominant Virus-Specific T-Cells in Recipients of Haploidentical Stem Cell Transplants
13. The Memorial Sloan-Kettering Experience With Allogeneic Stem Cell Transplantation For T Cell Non-Hodgkins Lymphomas
14. Allogeneic Human Mesenchymal Stem Cell Therapy (Prochymal®) As A Rescue Agent For Severe Treatment Resistant GVHD In Pediatric Patients
15. Adoptive Transfer Of EBV Specific T-Cells For Treatment Of Primary And Rituxan Resistant EBV Lymphomas Following Allogeneic Stem Cell Transplants (HSCT): Clinical, Viral And Immunologic Corelates
16. T-Cell Depleted Allografts From Unrelated Donors Confer A Low Risk Of Relapse On Patients With Hematologic Malignancies
17. Absolute Lymphocyte Count At Day 30 Predicts Survival In Recipients Of A T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
18. Ten allele high-resolution DNA typing has a direct impact on the disease free survival (DFS) in pediatric recipients of T-cell depleted (TCD) unrelated donor (URD) hematopoietic stem cell transplant (HCT)
19. Allogeneic bone marrow transplantation (BMT) for the treatment of children with very high risk acute lymphoblastic leukemia (ALL) in first remission (CR1)
20. Hematopoietic stem cell transplantation for the treatment of fanconi anemia using a fludarabine-based cytoreductive regimen and T-cell depleted grafts from alternative donors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.